Coegin Pharma AB
Coegin Pharma AB, a biotechnology company, engages in developing peptide-based products for hair growth and skin pigmentation in Sweden. The company develops Follicopeptide, a peptide designed to enhance hair growth; and NPP-4, a natural pigmentation peptide 4 works by facilitating the transport of melanin to the skin, mimicking the natural process that occurs during sun exposure or tanning beds.… Read more
Coegin Pharma AB (7Z6) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.419x
Based on the latest financial reports, Coegin Pharma AB (7Z6) has a cash flow conversion efficiency ratio of -0.419x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.88 Million) by net assets (€11.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Coegin Pharma AB - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Coegin Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Coegin Pharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coegin Pharma AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Canada Silver Cobalt Works Inc
OTCQB:CCWOF
|
0.428x |
|
General Commercial & Industrial S.A
AT:GEBKA
|
0.044x |
|
Chiangmai Frozen Foods Public Company Limited
BK:CM
|
-0.032x |
|
KD Chem Co. Ltd
KQ:221980
|
0.024x |
|
Snack Empire Holdings Limited
PINK:SNEHF
|
N/A |
|
Anvi Global Holdings, Inc.
OTCQB:ANVI
|
0.002x |
|
Viet Thang Corp
VN:TVT
|
N/A |
|
Algoma Steel Group Inc. Warrant
NASDAQ:ASTLW
|
-0.134x |
Annual Cash Flow Conversion Efficiency for Coegin Pharma AB (2021–2024)
The table below shows the annual cash flow conversion efficiency of Coegin Pharma AB from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €25.26 Million | €-23.64 Million | -0.936x | +71.32% |
| 2023-12-31 | €6.75 Million | €-22.03 Million | -3.263x | -79.36% |
| 2022-12-31 | €21.01 Million | €-38.23 Million | -1.819x | -69.96% |
| 2021-12-31 | €20.07 Million | €-21.48 Million | -1.070x | -- |